Instil Bio, Inc.
TILNasdaq
$7.42
↓ -1.2%Jul 17 close · end-of-day
Price
1Y↓ -71.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$50.3M
Enterprise Value
$45.3M
P/E
—
P/S
—
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$47.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-42.8%
ROIC
-41.1%
Debt / Equity
—
Net Cash
$5.0M
Return 1Y
-73.2%
Company profile
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL) Product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, and cervical cancer.
- CEO
- Bronson Crouch
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 410
- Headquarters
- Texas
- Website
- instilbio.com
Earnings
TIL Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.62↓ -85.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $138,000.00 | $0.00 | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$33.6M | -$155.6M | -$226.5M | -$159.2M | -$73.5M | -$78.6M |
| Net income | -$37.7M | -$156.8M | -$223.2M | -$156.1M | -$74.1M | -$71.4M |
| Diluted EPS | -$2.36 | -$1.48 | -$34.46 | -$24.00 | -$11.39 | -$10.70 |
| Operating cash flow | -$29.6M | -$122.1M | -$180.2M | -$82.0M | -$55.7M | -$36.6M |
| Free cash flow | -$80.4M | -$180.0M | -$264.8M | -$102.7M | -$55.7M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -24379.7% | — | — | — | — | — |
| Net margin | -27346.4% | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.1M | -$23.6M | -$11.8M | -$30.6M | -$23.4M | -$15.0M | -$9.6M | -$7.0M |
| Net income | -$14.9M | -$23.0M | -$11.9M | -$28.2M | -$21.4M | -$13.6M | -$8.2M | -$4.2M |
| Diluted EPS | -$2.29 | -$3.54 | -$1.82 | -$4.32 | -$3.24 | -$2.01 | -$1.13 | -$0.62 |
| Operating cash flow | -$10.6M | -$20.1M | -$10.6M | -$4.2M | -$14.8M | -$10.6M | -$7.1M | -$1.3M |
| Free cash flow | -$10.6M | -$20.1M | -$10.6M | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Feb 3, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-10 | Laumas Sandeep· CFO and CBO | Sale | 17,539 | $23.04 | $404,098.56 | filing |
| 2025-09-10 | Laumas Sandeep· CFO and CBO | Sale | 12,461 | $23.88 | $297,568.68 | filing |
| 2025-09-10 | Laumas Sandeep· CFO and CBO | Option exercise | 17,000 | $11.60 | $197,200.00 | filing |
| 2025-09-10 | Laumas Sandeep· CFO and CBO | Option exercise | 13,000 | $12.68 | $164,840.00 | filing |
Latest 4 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.